RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Diamyd Medical Stock

Diamyd Medical Revenue 2024

Diamyd Medical Revenue

3.03 M SEK

Ticker

DMYD B.ST

ISIN

SE0005162880

WKN

A1T90L

In 2024, Diamyd Medical's sales reached 3.03 M SEK, a 454.95% difference from the 546,000 SEK sales recorded in the previous year.

The Diamyd Medical Revenue history

YEARREVENUE (undefined SEK)GROSS MARGIN (%)
2026e3.03-445,25
2025e3.03-445,25
2024e3.03-445,25
20230.55-2470,88
20220.45-2470,26
20210.25-3637,94
20200.34-1911,14
20191.57-283,74
20180.73-644,90
20170.92-405,21
20160.76-1782,17
20150.51-2629,82

Diamyd Medical Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Diamyd Medical, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Diamyd Medical from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Diamyd Medical’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Diamyd Medical. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Diamyd Medical’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Diamyd Medical’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Diamyd Medical’s growth potential.

Diamyd Medical Revenue, EBIT and net profit per share

DateDiamyd Medical RevenueDiamyd Medical EBITDiamyd Medical Net Income
2026e3.03 M undefined-204.02 M undefined-197.55 M undefined
2025e3.03 M undefined-167.66 M undefined-161.36 M undefined
2024e3.03 M undefined-135.34 M undefined-130.07 M undefined
2023546,000 undefined-115.85 M undefined-116.07 M undefined
2022454,000 undefined-114.94 M undefined-103.52 M undefined
2021253,000 undefined-85.88 M undefined60.05 M undefined
2020341,000 undefined9.74 M undefined9.71 M undefined
20191.57 M undefined-36.57 M undefined-36.61 M undefined
2018726,000 undefined-44.04 M undefined-43.95 M undefined
2017922,000 undefined-25.52 M undefined-25.56 M undefined
2016757,000 undefined-18.52 M undefined-32.01 M undefined
2015513,000 undefined-21.57 M undefined-21.4 M undefined

Diamyd Medical stock margins

The Diamyd Medical margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Diamyd Medical. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Diamyd Medical.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Diamyd Medical's sales revenue. A higher gross margin percentage indicates that the Diamyd Medical retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Diamyd Medical's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Diamyd Medical's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Diamyd Medical's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Diamyd Medical. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Diamyd Medical's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Diamyd Medical Margin History

Diamyd Medical Gross marginDiamyd Medical Profit marginDiamyd Medical EBIT marginDiamyd Medical Profit margin
2026e-2,470.88 %-6,733.33 %-6,519.7 %
2025e-2,470.88 %-5,533.33 %-5,325.5 %
2024e-2,470.88 %-4,466.67 %-4,292.67 %
2023-2,470.88 %-21,217.22 %-21,258.79 %
2022-2,470.26 %-25,316.3 %-22,801.1 %
2021-3,637.94 %-33,944.67 %23,733.6 %
2020-1,911.14 %2,856.01 %2,847.21 %
2019-283.74 %-2,332.21 %-2,334.82 %
2018-644.9 %-6,065.56 %-6,054.13 %
2017-405.21 %-2,767.9 %-2,771.69 %
2016-2,470.88 %-2,445.97 %-4,228.27 %
2015-2,470.88 %-4,204.29 %-4,170.96 %

Diamyd Medical Aktienanalyse

What does Diamyd Medical do?

Diamyd Medical AB is a Swedish company specializing in the development of therapies for the treatment of autoimmune diseases, particularly type 1 diabetes. The company was founded in 1996 and is headquartered in Stockholm. It commercialized the discovery of Professor Johnny Ludvigsson at Linköping University, who developed a therapy based on the substance GAD (Glutamate Decarboxylase). The company has developed its own GAD-based product called Diamyd®, which is an injection solution that targets the patient's immune system to protect insulin production. In addition to Diamyd®, the company has developed other products based on similar active ingredients, the most important being Remygen®, which combines insulin and GAD to promote insulin production. Diamyd Medical has a broad portfolio of patents and licenses to protect its intellectual property and improve its technologies. The company collaborates closely with other researchers and industry stakeholders to develop and test new therapeutic approaches. Its business model involves licensing its products to pharmaceutical companies and other partners, who then assume responsibility for clinical development and marketing while Diamyd Medical focuses on research and development of new products. The company has expanded into other areas of medicine, including cancer immunotherapy, neurology, and cell therapy. It is currently working on a promising new technology that utilizes Treg cells (regulatory T cells) for the treatment of autoimmune diseases. Diamyd Medical is well-positioned to further expand its market position and drive the development of new therapies. Diamyd Medical ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Diamyd Medical's Sales Figures

The sales figures of Diamyd Medical originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Diamyd Medical’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Diamyd Medical's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Diamyd Medical’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Diamyd Medical stock

How much revenue did Diamyd Medical generate this year?

Diamyd Medical has achieved a revenue of 3.03 M SEK this year.

How much was the turnover of the company Diamyd Medical compared to the previous year?

The revenue of Diamyd Medical has increased by 454.95% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Diamyd Medical?

The revenue of Diamyd Medical is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Diamyd Medical measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Diamyd Medical so important for investors?

The revenue of Diamyd Medical is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Diamyd Medical pay?

Over the past 12 months, Diamyd Medical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Diamyd Medical is expected to pay a dividend of 0 SEK.

What is the dividend yield of Diamyd Medical?

The current dividend yield of Diamyd Medical is .

When does Diamyd Medical pay dividends?

Diamyd Medical pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Diamyd Medical?

Diamyd Medical paid dividends every year for the past 0 years.

What is the dividend of Diamyd Medical?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Diamyd Medical located?

Diamyd Medical is assigned to the 'Health' sector.

Wann musste ich die Aktien von Diamyd Medical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Diamyd Medical from 9/20/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 9/20/2024.

When did Diamyd Medical pay the last dividend?

The last dividend was paid out on 9/20/2024.

What was the dividend of Diamyd Medical in the year 2023?

In the year 2023, Diamyd Medical distributed 0 SEK as dividends.

In which currency does Diamyd Medical pay out the dividend?

The dividends of Diamyd Medical are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Diamyd Medical

Our stock analysis for Diamyd Medical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Diamyd Medical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.